Christopher Pieczonka
State University of New York System
5 Papers
11 Citations
Christopher Pieczonka is an academic researcher from State University of New York System. The author has contributed to research in topics: Testosterone & Sexual function. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Erectile function after anterior urethroplasty.
John W. Coursey,Allen F. Morey,Jack W. McAninch,Duncan J. Summerton,Charles L. Secrest,Paige C. White,Kennon S. Miller,Christopher Pieczonka,David A. Hochberg,Noel A. Armenakas +9 more
TL;DR: Overall anterior urethral reconstruction appears no more likely to cause long-term postoperative sexual dysfunction than circumcision, and men with a long stricture may be at increased risk for transient erectile changes.
149
Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts).
Fred Saad,James Bailen,Christopher Pieczonka,Daniel Saltzstein,Paul Sieber,David B. MacLean,Hongliang Shi,Hélène M. Faessel,Neal D. Shore +8 more
TL;DR: The primary endpoint was effective castration rate of TAK-385 (T < 50 ng/dL) from wk 5–24 and secondary endpoints included: safety, pharmacokinetics (PK), and PSA.
26
Pd28-01 testosterone lowering, psa response and quality of life in patients with advanced hormone sensitive prostate cancer receiving tak-385, an oral gnrh antagonist: phase 2 interim analysis
Neal D. Shore,James Bailen,Christopher Pieczonka,Daniel Saltzstein,Paul Sieber,David B. MacLean,Hongliang Shi,Hélène M. Faessel,Huamao Mark Lin,Yanyan Zhu,Fred Saad +10 more
6
Pd24-12 overall survival analysis of african american and caucasian patients receiving sipuleucel-t: preliminary data from the proceed registry
A. Oliver Sartor,Andrew J. Armstrong,Chiledum Ahaghotu,David G. McLeod,Matthew R. Cooperberg,David F. Penson,Philip W. Kantoff,Nicholas J. Vogelzang,Arif Hussain,Christopher Pieczonka,Nancy N. Chang,Celestia S. Higano +11 more
TL;DR: A multimodal treatment strategy inclusive of the NED endpoint for patients who present with disease that is beyond the limits of curability by any single modality should be considered to enable the evaluation of new approaches in order to prioritize large-scale testing in early stages of advanced disease.
5
Pi-06 late-breaking abstract: the 4kscoretm test as a predictor of high-grade prostate cancer on biopsy
Daniel W. Lin,Shawn M. McGee,Kimberly M. Rieger-Christ,Neal D. Shore,Christopher Pieczonka,James S. Cochran,Raoul S. Concepcion,Igor Dumbadze,Kenneth B. Deck,James Bailen,Ralph Jonathan Henderson,Paul Sieber,Timothy Dean Langford,Scott Asroff,Todd B. Waldmann +14 more
TL;DR: This competition is celebrating its 10th anniversary byrandomly selecting 10 winners from among the entries received over the past year.
2